第二代抗精神病药与短期死亡风险:安慰剂对照随机试验的系统综述与Meta分析
Meta分析发现,全因死亡、自然死亡、自杀及其他非自然死亡在用药组与安慰剂组间均无显著差异;但痴呆患者、老年人群、阿立哌唑治疗者及女性比例较高的研究中死亡率升高,且这些信号主要来自痴呆试验。
要点
- 总体及精神分裂症患者中,未发现抗精神病药增加死亡率的随机试验证据。
- 该分析仅反映短期急性治疗效应,不能外推长期死亡影响。
核心结论
- 总体及精神分裂症主要适应证上,随机试验未显示抗精神病药增加死亡率。
- 易感人群尤其是痴呆患者可能存在死亡风险增加。
- 本分析仅能评估导致短期死亡的急性治疗效应,无法评估长期死亡影响。
研究设计与样本
- 系统综述与Meta分析,纳入比较第二代抗精神病药与安慰剂的随机对照试验,覆盖多个诊断类别。
- 检索MEDLINE、EMBASE、Cochrane CENTRAL、BIOSIS、PsycINFO、PubMed、ClinicalTrials.gov及WHO ICTRP,末次检索2017年1月21日,并联系药企与监管机构获取试验。
- 采用共同效应模型以比值比(OR)合并结果,并进行亚组与Meta回归分析。
- 研究注册于PROSPERO,编号CRD42016033930。
主要发现
- 352项试验中300项(85%)持续时间≤13周(中位6周;IQR 4-10)。
关键数值与推荐
- 全因死亡为主要结局,另分析自然死亡、自杀及其他非自然死亡。
临床怎么用
- 对精神分裂症等主要适应证短期用药,可据随机试验证据说明未见死亡率增加。
- 对痴呆及老年患者处方第二代抗精神病药时,需警惕短期死亡风险升高并加强监测。
- 解读阿立哌唑及女性相关死亡信号时,应考虑其主要来源于痴呆试验,避免过度外推。
局限性
- 本Meta分析仅能评估导致短期死亡的急性治疗效应,无法评估抗精神病药对死亡率的长期影响。
- 多数试验持续时间短(中位6周),300项(85%)≤13周。
- 老年、阿立哌唑及女性相关死亡效应主要基于痴呆试验,解释需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acutely occurring, life-threatening side-effects of antipsychotic drugs might contribute to the reduced life expectancy observed in patients with severe mental disorders. We aimed to assess this hypothesis by doing a systematic review and meta-analysis of deaths occurring in placebo-controlled trials of antipsychotic drugs. METHODS: For this systematic review and meta-analysis, we included randomised controlled trials comparing second-generation antipsychotics with placebo across several diagnostic categories. We searched MEDLINE, EMBASE, Cochrane CENTRAL, BIOSIS, PsycINFO, PubMed, ClinicalTrials.gov, and WHO ICTRP from inception (the last search was done on Jan 21, 2017), and contacted pharmaceutical companies and regulatory authorities for further eligible trials. We examined mortality from any cause (the primary outcome) and mortality from natural causes, suicide, and other non-natural causes. We synthesised the results with odds ratios (ORs) in a common-effects meta-analysis. We investigated the effects of age, diagnostic category, sex, study duration, antipsychotic drug used, drug dose, and polypharmacy in subgroup and meta-regression analyses. This study is registered with PROSPERO, number CRD42016033930. FINDINGS: We identified 596 randomised controlled trials published between 1978 and 2017, comprising 108 747 participants. 352 studies (comprising 84 988 participants) with mortality data available constituted the main dataset for our meta-analysis. 207 (0·4%) deaths were reported in 53 804 patients on an antipsychotic drug and 99 (0·3%) deaths in 31 184 patients on placebo. 300 (85%) of 352 trials were 13 weeks (3 months) or shorter in duration (median 6 weeks; IQR 4-10). We found no evidence of a difference between antipsychotic drugs and placebo in mortality by any cause (OR 1·19; 95% CI 0·93-1·53), from natural causes (1·29; 0·85-1·94), from suicide (1·15; 0·47-2·81), and from other non-natural causes (1·55; 0·66-3·63). Most subgroup and meta-regression analyses did not indicate any important effect moderators. The exceptions were increased mortality in patients with dementia (OR 1·56; 95% CI 1·10-2·21), in elderly patients (1·38; 1·01-1·89), in aripiprazole-treated patients (2·20; 1·00-4·86), and in studies with a higher proportion of women (regression coefficient 0·025; 95% credible interval 0·010-0·040). However, the effects in elderly patients, aripiprazole-treated patients, and women were mainly based on the included dementia trials. For patients with schizophrenia there was no evidence of an increased mortality risk (OR 0·69; 95% CI 0·35-1·35). INTERPRETATION: Overall, and for the main indication of schizophrenia, there is no evidence from randomised trials that antipsychotic drugs increase mortality. However, vulnerable populations (particularly patients with dementia) might be at increased risk. This meta-analysis could only address acute treatment effects leading to death in the short-term, and not long-term effects of antipsychotic drugs on mortality. FUNDING: German Ministry of Education and Research.
引用
- Schneider-Thoma J, Efthimiou O, Huhn M, et al. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry. 2018. PMID: 30042077. doi:10.1016/S2215-0366(18)30177-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。